COMMUNIQUÉS West-GlobeNewswire

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
17/06/2026
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline [...]
Publication relative à des notifications de transparence
17/06/2026
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 17 juin 2026 , 22:30h CET / 17:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à [...]
Publication relating to transparency notifications
17/06/2026
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 17, 2026 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Law of May 2, 2007 on the [...]
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
17/06/2026
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on hand as of March 31, [...]
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17/06/2026
WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and [...]
Ontario Shores partners with community organizations to bring dementia care training to families
17/06/2026
Whitby, Ontario, June 17, 2026 (GLOBE NEWSWIRE) -- Ontario Shores Centre for Mental Health Sciences (Ontario Shores) announced today that it is partnering with the Alzheimer Society of Durham Region to expand access to [...]
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
17/06/2026
First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment i More than 3 million cases of cUTIs are treated annually in [...]
Le brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042
17/06/2026
COMMUNIQUÉ DE PRESSE LE BREVET D’AB SCIENCE CONCERNANT LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RÉSISTANT A ÉTÉ OFFICIELLEMENT DÉLIVRÉ AUX ÉTATS-UNIS AVEC UNE DURÉE DE PROTECTION [...]
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
17/06/2026
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2042 THIS POSITIVE DECISION FROM THE USA [...]
RESTEM to Present at BIO International Convention
17/06/2026
MIAMI, June 17, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that CEO, [...]
Applied Biologics Announces Completion of Planned Enrollment Activities in the CAMPX Randomized Controlled Trial Evaluating XWRAP®
17/06/2026
SCOTTSDALE, Ariz., June 17, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Compte-rendu de l’assemblée générale de TME Pharma
17/06/2026
Compte-rendu de l’assemblée générale de TME Pharma Berlin, Allemagne, le 17 juin 2026, 18 h 30 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie en phase clinique spécialisée dans le [...]
Eurobio Scientific: ERRATUM : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
17/06/2026
ERRATUM : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Paris, le 17 juin 2026 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro pour la [...]
Minutes of the TME Pharma Annual General Meeting
17/06/2026
Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of [...]
electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
17/06/2026
ROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will participate in the iAccess Alpha Virtual [...]
Merakris Therapeutics Awarded U.S. Department of Veterans Affairs Federal Supply Schedule Contract, Expanding Federal Market Access for Dermacyte® AC Matrix Amniotic Membrane Allograft
17/06/2026
Five-Year Contract Creates New Opportunities for Distribution Partners Serving VA and Federal Healthcare Facilities RESEARCH TRIANGLE PARK, N.C., June 17, 2026 (GLOBE NEWSWIRE) -- Merakris Therapeutics, Inc., a [...]
Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs
17/06/2026
Company to present at Planet Microcap Conference in Las Vegas between June 16-18 MELBOURNE, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) ("Gelteq" or the "Company"), a biotechnology company [...]
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
17/06/2026
100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy Complete [...]
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
17/06/2026
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients [...]

Pages